# Efficacy of Ocrelizumab in Autoimmune Encephalitis

> **NCT03835728** · PHASE2 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 3 (actual)

## Conditions studied

- Autoimmune Encephalitis

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT03835728
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-22
- **Primary completion:** 2020-10-02
- **Final completion:** 2020-10-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Failed to meet target enrollment and study was discontinued
- **Last updated:** 2021-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03835728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03835728, "Efficacy of Ocrelizumab in Autoimmune Encephalitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03835728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*